Biomnis has formed a partnership with ODPM in the personalized therapeutic sector of Oncology.

This partnership, based on a mutual and complementary knowledge of their medical and scientific activities, has enabled Biomnis and ODPM to realize a common ambition in personalised medicine: to develop reliable and innovative tests in order to enhance the therapeutic protocols of cancer patients.

From 1st September 2015, Biomnis laboratories will be exclusively performing the following tests:

• 5-FUODPM TOX TM Which enables the evaluation of the risk of toxicity to fluropyrimidines and to propose an initial dosage for the first treatment.
• 5-FUODPM Protocol TM Which enables via the testing of 5-fluorouracile (5-FU) levels on plasma, the adjustment of therapeutic doses for treatments in progress.

For further information on these tests

• Focus N° 54 – Tailoring treatment by fluoropyrimidines (5-Fluorouracile): towards a personalized medicine.